Our mission is to significantly improve
the lives of patients suffering from
immunological disorders by providing
effective and safe drugs for diseases
with high unmet medical needs.
Our lead drug candidate
cobitolimod has a new
and unique mechanism of
action to effectively and
safely treat ulcerative colitis.
InDex Pharmaceuticals
hosted an R&D day on
December 8, 2020
-
InDex Pharmaceuticals Holding AB (publ) interim report January – March 2021
May 5, 2021 Regulatory
-
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
May 4, 2021 Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q1 for January-March 2021 on May 5, 2021 at 08:00 a.m. CEST.
-
Annual General Meeting 2021
-
Interim report Q2 2021
-
Interim report Q3 2021
Our upcoming Phase III study CONCLUDE
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis
Proud partner of:
